RGNX

Berenberg Bank analyst Caroline Palomeque maintained a Buy rating on RegenXBio (RGNX - Research Report) today and set a price target of $61.00. The company's shares opened today at $33.40.Palomeque covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, RegenXBio, and Denali Therapeutics. According to TipRanks, Palomeque has an average return of -14.9% and a 31.68% success rate on recommended stocks. In addition to Berenberg Bank, RegenXBio also received a Buy from Morgan Stanley's Vikram Purohit in a report issued on August 10. However, on August 4, Wedbush maintained a Hold rating on RegenXBio (NASDAQ: RGNX).
https://www.tipranks.com/news/blurbs/berenberg-bank-reaffirms-their-buy-rating-on-regenxbio-rgnx?utm_source=advfn.com&utm_medium=referral